Hohimer Wealth Management LLC Has $563,000 Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Hohimer Wealth Management LLC decreased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 86.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,233 shares of the biopharmaceutical company's stock after selling 58,020 shares during the quarter. Hohimer Wealth Management LLC's holdings in Bristol Myers Squibb were worth $563,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in BMY. Pinney & Scofield Inc. acquired a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $25,000. Park Square Financial Group LLC acquired a new position in Bristol Myers Squibb during the 4th quarter valued at approximately $26,000. Transce3nd LLC acquired a new position in Bristol Myers Squibb during the 4th quarter valued at approximately $28,000. Global Wealth Strategies & Associates boosted its position in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in Bristol Myers Squibb during the 1st quarter valued at approximately $31,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Activity at Bristol Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.09% of the company's stock.

Bristol Myers Squibb Stock Performance

BMY stock traded down $0.64 during trading on Friday, reaching $47.43. 5,360,592 shares of the company's stock were exchanged, compared to its average volume of 12,771,033. Bristol Myers Squibb Company has a 1-year low of $41.61 and a 1-year high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The company's fifty day moving average price is $47.45 and its 200-day moving average price is $53.00. The firm has a market cap of $96.51 billion, a PE ratio of 17.77, a P/E/G ratio of 2.43 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the business earned ($4.40) EPS. The company's quarterly revenue was down 5.6% compared to the same quarter last year. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.23%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on BMY shares. Jefferies Financial Group reduced their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Argus upgraded Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Piper Sandler started coverage on Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. Finally, Morgan Stanley reduced their price objective on Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating for the company in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $57.69.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.